News Release | KYORIN Pharmaceutical Co., Ltd.

November 8, 2011Kyorin Pharmaceutical and Daiichi Sankyo Brasil Reach Agreement in Brazil for Activities Related to the Development and Marketing of Imidafenacin
April 5, 2011Release of "Uritos® OD Tablets 0.1mg" a Drug for Overactive Bladder
February 24, 2011Kyorin signed a License Agreement with Almirall on COPD Therapeutic Agent "Aclidinium Bromide" for Japan Territory
February 21, 2011KYORIN Group's Participation in Environmental Hygiene
November 12, 2010Approval Received for Orally Disintegrating Tablet of imidafenacin (INN), a Drug for Overactive Bladder
November 8, 2010Extension of License Rights Regarding KRP-203
June 8, 2010RELEASE OF "MUCODYNE® DS50%"
January 18, 2010MARKETING APPROVAL FOR "MUCODYNE® DS50%"
January 7, 2010Application filed for Orally Disintegrating Tablet of imidafenacin (INN), a Drug for Overactive Bladder
November 5, 2009Execution of License Agreement on Neramexane for Tinnitus with Merz Pharmaceuticals for Japan Territory
September 29, 2009KYORIN and Eisai Sign License Agreement for Development and Marketing of Uritos® Tablets in China, India, Sri Lanka and ASEAN Countries
July 27, 2009Grant of Marketing Right to Senju Pharmaceutical on Gatifloxacin Ophthalmic Solution in China
April 3, 2009Change of Representative Director and President at KYORIN Pharmaceutical
February 27, 2009Execution of Licensing and Supply Agreement on Uritos® Tablets with SPIMACO
January 29, 2009Paper on Clinical Trial of MUCODYNE® for COPD Patients (PEACE Study) Chosen for THE LANCET Paper of the Year 2008
December 24, 2008Approval for an additional regimen and dose of Pentasa®for the treatment of ulcerative colitis in its active phase
October 1, 2008Launch of Ulcerative Colitis and Crohn's Disease Therapeutic Agent Pentasa Tablets 500
September 30, 2008Discontinuation of Commercialization of Gatiflo(gatifloxacin) Tablets, a broad-spectrum antibacterial agent, in Japan
August 20, 2008Results of Overseas Clinical Studies for KRP-104, anti-diabetes agent
April 22, 2008Execution of License Agreement on Flutiform, an Anti-asthmatic Treatment, in Japan
April 18, 2008Launch of KIPRES Tablets 5mg
March 3, 2008Pentasa Tablets 250 Received Approvals For Additional Pediatric Indication
February 21, 2008Results of Analysis of the OASIS Study,a Large-Scale Health-Related QOL Study in Patients with Chronic Cerebral Infarction
January 30, 2008Execution of an Exclusive Patent License and Collaborative Research and Development Agreement with Merck & Co.,Inc. in the Field of Infectious Diseases
January 25, 2008KIPRES Received Approvals for Additional Indication to Relieve Symptoms of Allergic Rhinitis
October 12, 2007Discontinuation of Cooperation on Baynas Marketing for Treatment of Allergic Rhinitis by Kyorin Pharmaceutical Co.,Ltd. and Bayer Yakuhin,Ltd.
October 2, 2007Launch of "KIPRES" Oral Granules 4mg
September 26, 2007Merger between Kyorin Phamaceutical Co.,Ltd. and Nisshin Kyorin Pharmaceutical Co.,Ltd.
July 31, 2007Marketing Approval for "KIPRES" Oral Granules 4mg
April 28, 2006Kyorin Licensee Announces Decision to Stop Commercialization of Tequin
March 10, 2006On the Transition to a Holding - Company Structure
March 10, 2006On Kyorin Corporate Branding and the establishment of a New Corporate Mark & Logotype
March 7, 2006On the start of phase 1 for KRP-104, therapeutic agent for diabetes, in USA
November 18, 2005Notice of Group Reorganization in association with Transition to Holding-Company Structure through Share Exchange
November 9, 2005Favorable Ruling for Gatifloxacin Patent Dispute in Canada
August 1, 2005EXECUTION OF MOU WITH LG LIFE SCIENCES FOR KRP-197
June 13, 2005Dr.Program Co.,Ltd.Becomes a Wholly-Owned Subsidiary of Kyorin Pharmaceutical Co.,Ltd.
May 12, 2005Kyorin to Announce MIC-'09 Mid-Term Business Plans
March 31, 2005Kyorin Pharmaceutical to Acquire Toyo Pharmar Stock to Establish a Subsidiary
December 1, 2004Kyorin Pharmaceutical Announces Signing of Acquisition Agreement of ActivX Biosciences

1 2